In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

[Q]: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Medicare Information Act of 2011''.

SEC. 2. ANNUAL MEDICARE BENEFICIARY PART A CONTRIBUTIONS AND BENEFITS 
              STATEMENTS.

    (a) In General.--Part A of title XI of the Social Security Act is 
amended by inserting after section 1143 (42 U.S.C. 1320b-13) the 
following new section:

    ``annual medicare beneficiary part a contributions and benefits 
                               statements

    ``Sec. 1143A.  (a) Provision.--
            ``(1) In general.--Beginning not later than 2 years after 
        the date of the enactment of this section, the Secretary, in 
        coordination with the Commissioner of Social Security, shall 
        provide a statement described in subsection (b) (in this 
        section referred to as an `annual Medicare part A information 
        statement') on an annual basis to each eligible individual (as 
        defined in subsection (d)) for whom a current mailing address 
        can be determined through such methods as the Secretary 
        determines to be appropriate.
            ``(2) Coordination in single mailing with social security 
        account statements.--In order to avoid sending separate 
        statements under this section and section 1143 in the case of 
        an individual for whom a social security account statement is 
        provided under section 1143 and a separate annual Medicare part 
        A information statement would otherwise be provided under this 
        section, the Secretary shall coordinate with the Commissioner 
        of Social Security, whether through transmittal of data or 
        otherwise, in a manner so that the annual Medicare part A 
        information statement is included and sent with such social 
        security account statement.
            ``(3) Methodology.--
                    ``(A) In general.--The Secretary, in consultation 
                with the Commissioner of Social Security and the 
                Secretary of the Treasury, shall specify the 
                methodology to be used in estimating lifetime 
                contributions and lifetime benefits with respect to 
                annual Medicare part A information statements. Such 
                methodology for computing the lifespan of an individual 
                shall be the same methodology used for purposes of the 
                social security account statement under section 1143.
                    ``(B) Inclusion of description in statement.--The 
                Secretary shall include a brief description of the key 
                assumptions used in such methodology in the annual 
                Medicare part A information statements.
            ``(4) Summary of medicare part a program.--Each annual 
        Medicare part A information statement shall include a summary 
        of part A of the Medicare program. Such summary shall also 
        include a summary description of benefits and enrollment 
        options under parts B, C, and D of title XVIII, but shall 
        indicate that the information described in subsection (b) does 
        not include information related to contributions and benefits 
        under those parts.
    ``(b) Medicare Part A Information Statement Described.--In addition 
to the information described in paragraphs (3)(B) and (4) of subsection 
(a), each annual Medicare part A information statement for an eligible 
individual shall contain the following:
            ``(1) HI employee contributions.--The total contributions 
        described in section 1143(a)(2)(C) for the individual--
                    ``(A) for the most recent year for which data are 
                available;
                    ``(B) to the extent feasible, for previous periods 
                through the end of such year; and
                    ``(C) as projected for the individual during the 
                individual's lifetime.
        To the extent feasible, of such total contributions the portion 
        that is attributable to employer, employee, and self-employment 
        contributions.
            ``(2) Medicare part a benefits.--In the case of an eligible 
        individual--
                    ``(A) who, for such most recent year, was entitled 
                to benefits under part A of title XVIII, the total 
                value of such benefits provided to the individual under 
                such part as of the end of such year and, to the extent 
                feasible, the total value of such benefits for such 
                individual for previous periods through the end of such 
                year; and
                    ``(B) an estimate of the actuarial value of the 
                expected benefits under such part for the individual 
                during the individual's lifetime, including (but stated 
                separately) any benefits described in subparagraph (A).
            ``(3) Comparison.--An appropriate comparison of such 
        contributions with such benefits.
    ``(c) Records Retention.--The Secretary shall provide for the 
indefinite retention of information that--
            ``(1) is described in subsection (b), including benefits 
        described in subsection (b)(2); and
            ``(2) the Secretary has not discarded as of the date of the 
        enactment of this section.
    ``(d) Eligible Individual Defined.--In this section, the term 
`eligible individual' means an individual--
            ``(1) who has a social security account number;
            ``(2) who has attained age 25 or over; and
            ``(3) who is entitled to benefits under part A of title 
        XVIII or who, as of the end of the most recent year referred to 
        in subsection (b)(1)(A), has had any contributions described in 
        subsection (b)(1) made with respect to the individual during 
        such year or a previous year.''.
    (b) Inclusion of Social Security Account Statement for Those 
Receiving Annual Medicare Part A Information Statement.--Section 
1143(a)(3) of such Act (42 U.S.C. 1320b-13(a)(3)) is amended by adding 
at the end the following:
``Such term includes an individual not described in the previous 
sentence who is an eligible individual (as defined in subsection (d) of 
section 1143A) for whom an annual Medicare part A information statement 
is provided under such section.''.
[A]: Medicare Information Act of 2011 - Amends part A of title XI of the Social Security Act to direct the Secretary of Health and Human Services (HHS) to provide to each eligible individual annually a statement of Medicare part A (Hospital Insurance) contributions and benefits in coordination with the annual mailing of Social Security account statements.


[Q]: SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Preservation of Antibiotics for 
Medical Treatment Act of 2011''.

SEC. 2. FINDINGS.

    The Congress finds the following:
            (1) In January 2001, a Federal interagency task force--
                    (A) released an action plan to address the 
                continuing decline in effectiveness of antibiotics 
                against common bacterial infections, referred to as 
                antibiotic resistance;
                    (B) determined that antibiotic resistance is a 
                growing menace to all people and poses a serious threat 
                to public health; and
                    (C) cautioned that if current trends continue, 
                treatments for common infections will become 
                increasingly limited and expensive, and, in some cases, 
                nonexistent.
            (2) Antibiotic resistance, resulting in a reduced number of 
        effective antibiotics, may significantly impair the ability of 
        the United States to respond to terrorist attacks involving 
        bacterial infections or a large influx of hospitalized 
        patients.
            (3)(A) Any overuse or misuse of antibiotics contributes to 
        the spread of antibiotic resistance, whether in human medicine 
        or in agriculture.
            (B) Recognizing the public health threat caused by 
        antibiotic resistance, Congress took several steps to curb 
        antibiotic overuse in human medicine through amendments to the 
        Public Health Service Act (42 U.S.C. 201 et seq.) made by 
        section 102 of the Public Health Threats and Emergencies Act 
        (Public Law 106-505, title I; 114 Stat. 2315), but has not yet 
        addressed antibiotic overuse in agriculture.
            (4) In a March 2003 report, the National Academy of 
        Sciences stated that--
                    (A) a decrease in antimicrobial use in human 
                medicine alone will have little effect on the current 
                situation; and
                    (B) substantial efforts must be made to decrease 
                inappropriate overuse in animals and agriculture.
            (5) In 2010, the FDA determined that--
                    (A) 13.1 million kilograms of antibacterial drugs 
                were sold for use on food animals in the United States 
                in 2009;
                    (B) 3.3 million kilograms of antibacterial drugs 
                were used for human health in 2009; and
                    (C) therefore, 80 percent of antibacterial drugs 
                disseminated in the United States in 2009 were sold for 
                use on food animals, rather than being used for human 
                health.
            (6)(A) Large-scale, voluntary surveys by the Department of 
        Agriculture's Animal and Plant Health Inspection Service in 
        1999, 2001, and 2006 revealed that--
                    (i) 84 percent of grower-finisher swine farms, 83 
                percent of cattle feedlots, and 84 percent of sheep 
                farms administer antimicrobials in the feed or water 
                for health or growth promotion reasons; and
                    (ii) many of the antimicrobials identified are 
                identical or closely related to drugs used in human 
                medicine, including tetracyclines, macrolides, 
                Bacitracin, penicillins, and sulfonamides; and
            (B) these drugs are used in people to treat serious 
        diseases such as pneumonia, scarlet fever, rheumatic fever, 
        venereal disease, skin infections, and even pandemics like 
        malaria and plague, as well as bioterrorism agents like 
        smallpox and anthrax.
            (7) Many scientific studies confirm that the nontherapeutic 
        use of antibiotics in agricultural animals contributes to the 
        development of antibiotic-resistant bacterial infections in 
        people.
            (8) The periodical entitled ``Clinical Infectious 
        Diseases'' published a report in June 2002, that--
                    (A) was based on a 2-year review by experts in 
                human and veterinary medicine, public health, 
                microbiology, biostatistics, and risk analysis, of more 
                than 500 scientific studies on the human health impacts 
                of antimicrobial use in agriculture; and
                    (B) recommended that antimicrobial agents should no 
                longer be used in agriculture in the absence of 
                disease, but should be limited to therapy for diseased 
                individual animals and prophylaxis when disease is 
                documented in a herd or flock.
            (9) The United States Geological Survey reported in March 
        2002 that--
                    (A) antibiotics were present in 48 percent of the 
                streams tested nationwide; and
                    (B) almost half of the tested streams were 
                downstream from agricultural operations.
            (10) An April 1999 study by the General Accounting Office 
        concluded that resistant strains of 3 microorganisms that cause 
        food-borne illness or disease in humans (Salmonella, 
        Campylobacter, and E. coli) are linked to the use of 
        antibiotics in animals.
            (11) Epidemiological research has shown that resistant 
        Salmonella and Campylobacter infections are associated with 
        increased numbers of ill patients and bloodstream infections, 
        and increased death.
            (12) In 2010, the peer-reviewed journal Molecular Cell 
        published a study demonstrating that low-dosage use of 
        antibiotics causes a dramatic increase in genetic mutation, 
        raising new concerns about the agricultural practice of using 
        low-dosage antibiotics in order to stimulate growth promotion 
        and routinely prevent disease in unhealthy conditions.
            (13)(A) In January 2003, Consumer Reports published test 
        results on poultry products bought in grocery stores nationwide 
        showing disturbingly high levels of Campylobacter and 
        Salmonella bacteria that were resistant to the antibiotics used 
        to treat food-borne illnesses.
            (B) The Food and Drug Administration's National 
        Antimicrobial Resistance Monitoring System routinely finds that 
        retail meat products are contaminated with bacteria (including 
        the foodborne pathogens Campylobacter and Salmonella) that are 
        resistant to antibiotics important in human medicine.
            (C) In December 2007, the USDA issued a fact sheet on the 
        recently recognized link between antimicrobial drug use in 
        animals and Methicillin Resistant Staphylococcus Aureas (MRSA) 
        infections in humans.
            (14) In October 2001, the New England Journal of Medicine 
        published an editorial urging a ban on nontherapeutic use of 
        medically important antibiotics in animals.
            (15)(A) In 1998, the National Academy of Sciences noted 
        that antibiotic-resistant bacteria generate a minimum of 
        $4,000,000,000 to $5,000,000,000 in costs to United States 
        society and individuals yearly.
            (B) In 2009, Cook County Hospital and the Alliance for 
        Prudent Use of Antibiotics estimated that the total health care 
        cost of antibiotic resistant infections in the United States 
        was between $16,600,000,000 and $26,000,000,000 annually.
            (16) The American Medical Association, the American Public 
        Health Association, the National Association of County and City 
        Health Officials, and the National Campaign for Sustainable 
        Agriculture are among the more than 300 organizations 
        representing health, consumer, agricultural, environmental, 
        humane, and other interests that have supported enactment of 
        legislation to phase out nontherapeutic use in farm animals of 
        medically important antibiotics.
            (17) In 2010, the Danish Veterinary and Food Administration 
        testified that the Danish ban of the non-therapeutic use of 
        antibiotics in food animal production resulted in a marked 
        reduction in antimicrobial resistance in multiple bacterial 
        species, including Campylobacter and Enterococci.
            (18) In 2009, the Congressional Research Service concluded 
        that restrictions overseas on the use of antimicrobial drugs in 
        the production of livestock could impact U.S. export markets 
        for livestock and poultry.
            (19) The Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
        301 et seq.)--
                    (A) requires that all drugs be shown to be safe 
                before the drugs are approved; and
                    (B) places the burden on manufacturers to account 
                for health consequences and prove safety.
            (20)(A) The Food and Drug Administration recently modified 
        the drug approval process for antibiotics to recognize the 
        development of resistant bacteria as an important aspect of 
        safety, but most antibiotics currently used in animal 
        production systems for nontherapeutic purposes were approved 
        before the Food and Drug Administration began considering 
        resistance during the drug-approval process.
            (B) The Food and Drug Administration has not established a 
        schedule for reviewing those existing approvals.
            (21) Certain non-routine uses of antibiotics in animal 
        agriculture are legitimate to prevent animal disease.
            (22) An April 2004 study by the General Accounting Office--
                    (A) concluded that Federal agencies do not collect 
                the critical data on antibiotic use in animals that 
                they need to support research on human health risks; 
                and
                    (B) recommends that the Department of Agriculture 
                and the Department of Health and Human Services develop 
                and implement a plan to collect data on antibiotic use 
                in animals.

SEC. 3. PURPOSE.

    The purpose of this Act is to preserve the effectiveness of 
medically important antibiotics used in the treatment of human and 
animal diseases by reviewing the safety of certain antibiotics for 
nontherapeutic purposes in food-producing animals.

SEC. 4. PROOF OF SAFETY OF CRITICAL ANTIMICROBIAL ANIMAL DRUGS.

    (a) Definitions.--Section 201 of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 321) is amended by adding at the end the 
following:
    ``(ss) Critical Antimicrobial Animal Drug.--The term `critical 
antimicrobial animal drug' means a drug that--
            ``(1) is intended for use in food-producing animals; and
            ``(2) is composed wholly or partly of--
                    ``(A) any kind of penicillin, tetracycline, 
                macrolide, lincosamide, streptogramin, aminoglycoside, 
                or sulfonamide; or
                    ``(B) any other drug or derivative of a drug that 
                is used in humans or intended for use in humans to 
                treat or prevent disease or infection caused by 
                microorganisms.
    ``(tt) Nontherapeutic Use.--The term `nontherapeutic use', with 
respect to a critical antimicrobial animal drug, means any use of the 
drug as a feed or water additive for an animal in the absence of any 
clinical sign of disease in the animal for growth promotion, feed 
efficiency, weight gain, routine disease prevention, or other routine 
purpose.''.
    (b) Applications Pending or Submitted After Enactment.--Section 
512(d)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
360b(d)(1)) is amended--
            (1) in the first sentence--
                    (A) in subparagraph (H), by striking ``or'' at the 
                end;
                    (B) in subparagraph (I), by inserting ``or'' at the 
                end; and
                    (C) by inserting after subparagraph (I) the 
                following:
                    ``(J) with respect to a critical antimicrobial 
                animal drug or a drug of the same chemical class as a 
                critical antimicrobial animal drug, the applicant has 
                failed to demonstrate that there is a reasonable 
                certainty of no harm to human health due to the 
                development of antimicrobial resistance that is 
                attributable, in whole or in part, to the 
                nontherapeutic use of the drug; or''; and
            (2) in the second sentence, by striking ``(A) through (I)'' 
        and inserting ``(A) through (J)''.
    (c) Phased Elimination of Nontherapeutic Use in Animals of Critical 
Antimicrobial Animal Drugs Important for Human Health.--Section 512 of 
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b) is amended by 
adding at the end the following:
    ``(q) Phased Elimination of Nontherapeutic Use in Animals of 
Critical Antimicrobial Animal Drugs Important for Human Health.--
            ``(1) Applicability.--This subsection applies to the 
        nontherapeutic use in a food-producing animal of a drug--
                    ``(A)(i) that is a critical antimicrobial animal 
                drug; or
                    ``(ii) that is of the same chemical class as a 
                critical antimicrobial animal drug; and
                    ``(B)(i) for which there is in effect an approval 
                of an application or an exemption under subsection (b), 
                (i), or (j) of section 505; or
                    ``(ii) that is otherwise marketed for use.
            ``(2) Withdrawal.--The Secretary shall withdraw the 
        approval of a nontherapeutic use in food-producing animals 
        described in paragraph (1) on the date that is 2 years after 
        the date of enactment of this subsection unless--
                    ``(A) before the date that is 2 years after the 
                date of the enactment of this subsection, the Secretary 
                makes a final written determination that the holder of 
                the approved application has demonstrated that there is 
                a reasonable certainty of no harm to human health due 
                to the development of antimicrobial resistance that is 
                attributable in whole or in part to the nontherapeutic 
                use of the drug; or
                    ``(B) before the date specified in subparagraph 
                (A), the Secretary makes a final written determination 
                under this subsection, with respect to a risk analysis 
                of the drug conducted by the Secretary and other 
                relevant information, that there is a reasonable 
                certainty of no harm to human health due to the 
                development of antimicrobial resistance that is 
                attributable in whole or in part to the nontherapeutic 
                use of the drug.
            ``(3) Exemptions.--Except as provided in paragraph (5), if 
        the Secretary grants an exemption under section 505(i) for a 
        drug that is a critical antimicrobial animal drug, the 
        Secretary shall rescind each approval of a nontherapeutic use 
        in a food-producing animal of the critical antimicrobial animal 
        drug, or of a drug in the same chemical class as the critical 
        antimicrobial animal drug, as of the date that is 2 years after 
        the date on which the Secretary grants the exemption.
            ``(4) Approvals.--Except as provided in paragraph (5), if 
        an application for a drug that is a critical antimicrobial 
        animal drug is submitted to the Secretary under section 505(b), 
        the Secretary shall rescind each approval of a nontherapeutic 
        use in a food-producing animal of the critical antimicrobial 
        animal drug, or of a drug in the same chemical class as the 
        critical antimicrobial animal drug, as of the date that is 2 
        years after the date on which the application is submitted to 
        the Secretary.
            ``(5) Exception.--Paragraph (3) or (4), as the case may be, 
        shall not apply if--
                    ``(A) before the date on which approval would be 
                rescinded under that paragraph, the Secretary makes a 
                final written determination that the holder of the 
                application for the approved nontherapeutic use has 
                demonstrated that there is a reasonable certainty of no 
                harm to human health due to the development of 
                antimicrobial resistance that is attributable in whole 
                or in part to the nontherapeutic use in the food-
                producing animal of the critical antimicrobial animal 
                drug; or
                    ``(B) before the date specified in subparagraph 
                (A), the Secretary makes a final written determination 
                under this subsection, with respect to a risk analysis 
                of the critical antimicrobial animal drug conducted by 
                the Secretary and any other relevant information, that 
                there is a reasonable certainty of no harm to human 
                health due to the development of antimicrobial 
                resistance that is attributable in whole or in part to 
                the nontherapeutic use of the drug.''.

SEC. 5. COMMITTEE HEARINGS ON IMPLEMENTATION.

    (a) In General.--The Committee on Energy and Commerce of the House 
of Representatives and the Committee on Energy of the Senate shall each 
hold a hearing on the implementation by the Commissioner of Food and 
Drugs of section 512(q) of the Federal Food, Drug, and Cosmetic Act, as 
added by section 4 of this Act.
    (b) Exercise of Rulemaking Authority.--Subsection (a) is enacted--
            (1) as an exercise of the rulemaking power of the House of 
        Representatives and Senate, and, as such, they shall be 
        considered as part of the rules of the House or Senate (as the 
        case may be), and such rules shall supersede any other rule of 
        the House or Senate only to the extent that rule is 
        inconsistent therewith; and
            (2) with full recognition of the constitutional right of 
        either House to change such rules (so far as relating to the 
        procedure in such House) at any time, in the same manner, and 
        to the same extent as in the case of any other rule of the 
        House or Senate.
[A]: Preservation of Antibiotics for Medical Treatment Act of 2011 - Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary of Health and Human Services (HHS) to deny an application for a new animal drug that is a critical antimicrobial animal drug unless the applicant demonstrates that there is a reasonably certainty of no harm to human health due to the development of antimicrobial resistance attributable to the nontherapeutic use of the drug. Defines "critical antimicrobial animal drug" as a drug intended for use in food-producing animals that contains specified antibiotics or other drugs used in humans to treat or prevent disease or infection caused by microorganisms.

Requires the Secretary to withdraw approval of a nontherapeutic use of such drugs in food-producing animals two years after the date of enactment of this Act unless certain safety requirements are met. Directs specified congressional committees to hold hearings on the implementation of such a withdrawal of approval.


[Q]: TITLE I--EXTENSION OF PERIOD FOR REIMBURSEMENT UNDER FISHERMEN'S 
                         PROTECTIVE ACT OF 1967

SEC. 101. SHORT TITLE.

    This title may be cited as the ``Fishermen's Protective Act 
Amendments of 2000''.

SEC. 102. EXTENSION OF PERIOD FOR REIMBURSEMENT UNDER FISHERMEN'S 
              PROTECTIVE ACT OF 1967.

    (a) In General.--Section 7(e) of the Fishermen's Protective Act of 
1967 (22 U.S.C. 1977(e)) is amended by striking ``2000'' and inserting 
``2003''.
    (b) Clerical Amendment.--Section 7(a)(3) of the Fishermen's 
Protective Act of 1967 (22 U.S.C. 1977(a)(3)) is amended by striking 
``Secretary of the Interior'' and inserting ``Secretary of Commerce''.

                      TITLE II--YUKON RIVER SALMON

SEC. 201. SHORT TITLE.

    This title may be cited as the ``Yukon River Salmon Act of 2000''.

SEC. 202. YUKON RIVER SALMON PANEL.

    (a) Establishment.--
        (1) In general.--There shall be a Yukon River Salmon Panel (in 
    this title referred to as the ``Panel'').
        (2) Functions.--The Panel shall--
            (A) advise the Secretary of State regarding the negotiation 
        of any international agreement with Canada relating to 
        management of salmon stocks originating from the Yukon River in 
        Canada;
            (B) advise the Secretary of the Interior regarding 
        restoration and enhancement of such salmon stocks; and
            (C) perform other functions relating to conservation and 
        management of such salmon stocks as authorized by this or any 
        other title.
        (3) Designation as united states representatives on bilateral 
    body.--The Secretary of State may designate the members of the 
    Panel to be the United States representatives on any successor to 
    the panel established by the interim agreement for the conservation 
    of salmon stocks originating from the Yukon River in Canada agreed 
    to through an exchange of notes between the Government of the 
    United States and the Government of Canada on February 3, 1995, if 
    authorized by any agreement establishing such successor.
    (b) Membership.--
        (1) In general.--The Panel shall be comprised of six members, 
    as follows:
            (A) One member who is an official of the United States 
        Government with expertise in salmon conservation and 
        management, who shall be appointed by the Secretary of State.
            (B) One member who is an official of the State of Alaska 
        with expertise in salmon conservation and management, who shall 
        be appointed by the Governor of Alaska.
            (C) Four members who are knowledgeable and experienced with 
        regard to the salmon fisheries on the Yukon River, who shall be 
        appointed by the Secretary of State in accordance with 
        paragraph (2).
        (2) Appointees from alaska.--(A) The Secretary of State shall 
    appoint the members under paragraph (1)(C) from a list of at least 
    three individuals nominated for each position by the Governor of 
    Alaska.
        (B) In making the nominations, the Governor of Alaska may 
    consider suggestions for nominations provided by organizations with 
    expertise in Yukon River salmon fisheries.
        (C) The Governor of Alaska may make appropriate nominations to 
    allow for appointment of, and the Secretary of State shall appoint, 
    under paragraph (1)(C)--
            (i) at least one member who is qualified to represent the 
        interests of Lower Yukon River fishing districts; and
            (ii) at least one member who is qualified to represent the 
        interests of Upper Yukon River fishing districts.
        (D) At least one of the members appointed under paragraph 
    (1)(C) shall be an Alaska Native.
        (3) Alternates.--(A) The Secretary of State may designate an 
    alternate Panel member for each Panel member the Secretary appoints 
    under paragraphs (1)(A) and (C), who meets the same qualifications, 
    to serve in the absence of the Panel member.
        (B) The Governor of the State of Alaska may designate an 
    alternative Panel member for the Panel member appointed under 
    subsection (b)(1)(B), who meets the same qualifications, to serve 
    in the absence of that Panel member.
    (c) Term Length.--Panel members and alternate Panel members shall 
serve 4-year terms. Any individual appointed to fill a vacancy 
occurring before the expiration of any term shall be appointed for the 
remainder of that term.
    (d) Reappointment.--Panel members and alternate Panel members shall 
be eligible for reappointment.
    (e) Decisions.--Decisions of the Panel shall be made by the 
consensus of the Panel members appointed under subparagraphs (B) and 
(C) of subsection (b)(1).
    (f) Consultation.--In carrying out their functions, Panel members 
may consult with such other interested parties as they consider 
appropriate.

SEC. 203. ADVISORY COMMITTEE.

    (a) Appointments.--The Governor of Alaska may establish and appoint 
an advisory committee of not less than eight, but not more than 12, 
individuals who are knowledgeable and experienced with regard to the 
salmon fisheries on the Yukon River. At least two of the advisory 
committee members shall be Alaska Natives. Members of the advisory 
committee may attend all meetings of the Panel, and shall be given the 
opportunity to examine and be heard on any matter under consideration 
by the Panel.
    (b) Compensation.--The members of such advisory committee shall 
receive no compensation for their services.
    (c) Term Length.--Members of such advisory committee shall serve 2-
year terms. Any individual appointed to fill a vacancy occurring before 
the expiration of any term shall be appointed for the remainder of that 
term.
    (d) Reappointment.--Members of such advisory committee shall be 
eligible for reappointment.

SEC. 204. EXEMPTION.

    The Federal Advisory Committee Act (5 U.S.C. App.) shall not apply 
to the Panel or to an advisory committee established under section 203.

SEC. 205. AUTHORITY AND RESPONSIBILITY.

    (a) Responsible Management Entity.--The State of Alaska Department 
of Fish and Game shall be the responsible management entity for the 
United States for the purposes of any agreement with Canada regarding 
management of salmon stocks originating from the Yukon River in Canada.
    (b) Effect of Designation.--The designation under subsection (a) 
shall not be considered to expand, diminish, or otherwise change the 
management authority of the State of Alaska or the Federal Government 
with respect to fishery resources.
    (c) Recommendations of Panel.--In addition to recommendations made 
by the Panel to the responsible management entities in accordance with 
any agreement with Canada regarding management of salmon stocks 
originating from the Yukon River in Canada, the Panel may make 
recommendations concerning the conservation and management of salmon 
originating in the Yukon River to the Department of the Interior, the 
Department of Commerce, the Department of State, the North Pacific 
Fishery Management Council, and other Federal or State entities as 
appropriate. Recommendations by the Panel shall be advisory in nature.

SEC. 206. ADMINISTRATIVE MATTERS.

    (a) Compensation.--Panel members and alternate Panel members who 
are not State or Federal employees shall receive compensation at the 
daily rate of GS-15 of the General Schedule when engaged in the actual 
performance of duties.
    (b) Travel and Other Necessary Expenses.--Travel and other 
necessary expenses shall be paid by the Secretary of the Interior for 
all Panel members, alternate Panel members, and members of any advisory 
committee established under section 203 when engaged in the actual 
performance of duties.
    (c) Treatment as Federal Employees.--Except for officials of the 
United States Government, all Panel members, alternate Panel members, 
and members of any advisory committee established under section 203 
shall not be considered to be Federal employees while engaged in the 
actual performance of duties, except for the purposes of injury 
compensation or tort claims liability as provided in chapter 81 of 
title 5, United States Code, and chapter 71 of title 28, United States 
Code.

SEC. 207. YUKON RIVER SALMON STOCK RESTORATION AND ENHANCEMENT 
              PROJECTS.

    (a) In General.--The Secretary of the Interior, in consultation 
with the Secretary of Commerce, may carry out projects to restore or 
enhance salmon stocks originating from the Yukon River in Canada and 
the United States.
    (b) Cooperation With Canada.--If there is in effect an agreement 
between the Government of the United States and the Government of 
Canada for the conservation of salmon stocks originating from the Yukon 
River in Canada that includes provisions governing projects authorized 
under this section, then--
        (1) projects under this section shall be carried out in 
    accordance with that agreement; and
        (2) amounts available for projects under this section--
            (A) shall be expended in accordance with the agreement; and
            (B) may be deposited in any joint account established by 
        the agreement to fund such projects.

SEC. 208. AUTHORIZATION OF APPROPRIATIONS.

    There are authorized to be appropriated to the Secretary of the 
Interior to carry out this title $4,000,000 for each of fiscal years 
2000, 2001, 2002, and 2003, of which--
        (1) such sums as are necessary shall be available each fiscal 
    year for travel expenses of Panel members, alternate Panel members, 
    United States members of the Joint Technical Committee established 
    by paragraph C.2 of the memorandum of understanding concerning the 
    Pacific Salmon Treaty between the Government of the United States 
    and the Government of Canada (recorded January 28, 1985), and 
    members of an advisory committee established and appointed under 
    section 203, in accordance with Federal Travel Regulations and 
    sections 5701, 5702, 5704 through 5708, and 5731 of title 5, United 
    States Code;
        (2) such sums as are necessary shall be available for the 
    United States share of expenses incurred by the Joint Technical 
    Committee and any panel established by any agreement between the 
    Government of the United States and the Government of Canada for 
    restoration and enhancement of salmon originating in Canada;
        (3) up to $3,000,000 shall be available each fiscal year for 
    activities by the Department of the Interior and the Department of 
    Commerce for survey, restoration, and enhancement activities 
    related to salmon stocks originating from the Yukon River in 
    Canada, of which up to $1,200,000 shall be available each fiscal 
    year for Yukon River salmon stock restoration and enhancement 
    projects under section 207(b); and
        (4) $600,000 shall be available each fiscal year for 
    cooperative salmon research and management projects in the portion 
    of the Yukon River drainage located in the United States that are 
    recommended by the Panel.

               TITLE III--FISHERY INFORMATION ACQUISITION

SEC. 301. SHORT TITLE.

    This title may be cited as the ``Fisheries Survey Vessel 
Authorization Act of 2000''.

SEC. 302. ACQUISITION OF FISHERY SURVEY VESSELS.

    (a) In General.--The Secretary, subject to the availability of 
appropriations, may in accordance with this section acquire, by 
purchase, lease, lease-purchase, or charter, and equip up to six 
fishery survey vessels in accordance with this section.
    (b) Vessel Requirements.--Any vessel acquired and equipped under 
this section must--
        (1) be capable of--
            (A) staying at sea continuously for at least 30 days;
            (B) conducting fishery population surveys using 
        hydroacoustic, longlining, deep water, and pelagic trawls, and 
        other necessary survey techniques; and
            (C) conducting other work necessary to provide fishery 
        managers with the accurate and timely data needed to prepare 
        and implement fishery management plans; and
        (2) have a hull that meets the International Council for 
    Exploration of the Sea standard regarding acoustic quietness.
    (c) Authorization.--To carry out this section there are authorized 
to be appropriated to the Secretary $60,000,000 for each of fiscal 
years 2002 and 2003.

                        TITLE IV--MISCELLANEOUS

SEC. 401. FISHERIES RESEARCH VESSEL PROCUREMENT.

    Notwithstanding section 644 of title 15, United States Code, and 
section 19.502-2 of title 48, Code of Federal Regulations, the 
Secretary of Commerce shall seek to procure Fisheries Research Vessels 
through full and open competition from responsible United States 
shipbuilding companies irrespective of size.

                               Speaker of the House of Representatives.

                            Vice President of the United States and    
                                               President of the Senate.
[A]:
Title II: Yukon River Salmon - Yukon River Salmon Act of 1999 - Establishes the Yukon River Salmon Panel. Includes among its duties: (1) advising the Secretary of State on the negotiation of any international agreement with Canada regarding management of salmon stocks originating from the Yukon River in Canada; and (2) advising the Secretary of the Interior on restoration and enhancement of those stocks. Authorizes the Secretary of State to designate Panel members to be the U.S. representatives on any successor to the panel established by a specified interim agreement between the United States and Canada for the conservation of salmon stocks, if authorized by any agreement establishing the successor.(Sec. 203) Authorizes the Governor of Alaska to establish and appoint an advisory committee of individuals knowledgeable regarding the Yukon River salmon fisheries. Allows committee members to attend all Panel meetings and requires that they be given the opportunity to examine and be heard on any Panel matter.(Sec. 205) Makes the State of Alaska Department of Fish and Game the responsible U.S. management entity for the purposes of any agreement with Canada regarding management of salmon stocks originating from the Yukon River.(Sec. 207) Authorizes the Secretary of the Interior to carry out projects to restore or enhance such salmon stocks.(Sec. 208) Authorizes appropriations.Title III: Fishery Information Acquisition - Fisheries Survey Vessel Authorization Act of 1999 - Authorizes the Secretary of Commerce to acquire and equip up to six fishery survey vessels. Authorizes appropriations.Title IV: Miscellaneous - Amends the Atlantic Tunas Convention Act of 1975 to make it unlawful for any person, other than a person holding a purse seine permit, to: (1) use an aircraft to locate or otherwise assist in fishing for, catching, or retaining Atlantic bluefin tuna; or (2) catch, possess, or retain Atlantic bluefin tuna located by use of an aircraft.(Sec. 402) Directs the Secretary of Commerce, notwithstanding specified provisions of the Small Business Act relating to awards or contracts and notwithstanding specified Federal regulations, to seek to procure Fisheries Research Vessels through full and open competition from United States shipbuilding companies irrespective of size. Requires, as an award criterion, that at least 40 percent of the value of the total construction and outfitting contract be obtained from small business concerns either directly or through subcontracting.